Mass. Movers

FDA reviews Biogen’s hemophilia A drug

George Scangos is CEO of Weston-based Biogen Idec.

Reuters/File 2011

George Scangos is CEO of Weston-based Biogen Idec.

Biogen Idec Inc. said the Food and Drug Administration has agreed to review its experimental drug Eloctate as a treatment for hemophilia A. It would be injected once or twice a week; existing treatments are taken three or four times a week. Hemophilia A, which is inherited, occurs in one of 5,000 male births. Those with the disease don’t have enough factor VIII, a blood clotting protein. The FDA in March started reviewing Biogen Idec’s Alprolix for hemophilia B, which is even rarer and caused by a different deficiency.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of